Boston Harbor skyline
Biotech

How Boston biotechs cope with shallower pool of seed funding

With the average seed round dropping 40% in the first half of the year, CEOs and investors told Fierce where they think the industry is heading.
Will Maddox Oct 16, 2026 7:00am
China flag against blue sky

China looks to ban foreign acquisitions of key biotech platforms

Oct 16, 2026 10:38am
Estuary river tributary

Estuary emerges with $103M for kidney disease gene therapies

Oct 16, 2026 6:30am
Stock market IPO share price

City scores $200M IPO as Frazier takes biotech SPAC to Nasdaq

Oct 16, 2026 2:47am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Bausch + Lomb CEO heads for exit once more—Chutes & Ladders

Oct 16, 2026 8:30am
fundraise tracker 2026

Fierce Biotech Fundraising Tracker '26: Estuary, OMass & more

Oct 16, 2026 6:30am
More News

OrbiMed’s largest-ever Asian fund contributes to $3B war chest

Oct 15, 2026 9:18am

AstraZeneca, insitro ink $1.5B AI-enabled target discovery deal

Oct 15, 2026 6:00am

Rebranded Galapagos finally finds buyer for cell therapies

Oct 15, 2026 4:09am

Iambic goes public with $150M IPO to accelerate cancer pipeline

Oct 15, 2026 2:30am